title: Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer.
abstract: Histological therapeutic effects of neoadjuvant hormone therapy (NHT) in prostatic cancer were examined, focusing on the association with neuroendocrine differentiation (NED), using 69 radical prostatectomy cases. The effects of NHT were classified into 3 grades based on the extent of tumor degeneration as observed with hematoxylin and eosin staining. NED cells in the cancer were semi-quantified into 4 grades (negative, 1+, 2+, and 3+) by immunohistochemical staining of chromogranin A (CgA). According to the therapeutic effects, the cases are divided as follows: good response in 26 patients, intermediate in 20, poor in 23. The histological therapeutic effects were significantly weaker in the CgA-positive group than the CgA-negative group (p=0.02). A close relationship between the extent of CgA expression and the histological response was also demonstrated (p=0.007). In the biopsy specimens before NHT, CgA was positive in 46% (32/69) and there was no significant difference in histological therapeutic effects between the positive and negative groups. However, the therapeutic effects were significantly weaker in 22 CgA-positive cases for both biopsy and prostatectomy specimens than in 18 CgA-negative cases for both specimens (p=0.001). In conclusion, although it seems difficult to predict the therapeutic effects of NHT using the biopsy specimens of prostatic cancer, we believe that NED is negatively associated with histological response of prostatic cancer to NHT.
authors.affiliation: Department of Urology, School of Medicine, Tokai University, Bohseidai, Isehara, Kanagawa 259-1193, Japan.
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Tokunaga
authors.forename: Masanori
authors.initials: M
authors.lastname: Yasuda
authors.forename: R Yoshiyuki
authors.initials: RY
authors.lastname: Osamura
authors.forename: Johbu
authors.initials: J
authors.lastname: Itoh
authors.forename: Masaya
authors.initials: M
authors.lastname: Mukai
authors.forename: Masanori
authors.initials: M
authors.lastname: Shima
authors.forename: Yukio
authors.initials: Y
authors.lastname: Usui
authors.forename: Aiichiro
authors.initials: A
authors.lastname: Masuda
authors.forename: Hideshi
authors.initials: H
authors.lastname: Miyakita
authors.forename: Toshiro
authors.initials: T
authors.lastname: Terachi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D002454:Cell Differentiation; D053379:Chromogranin A; D002864:Chromogranins / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
chemical_list: D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D053379:Chromogranin A; D002864:Chromogranins